EUR 1.24
(-2.97%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 4.02 Million EUR | -12.48% |
2022 | 4.59 Million EUR | -49.3% |
2021 | 9.07 Million EUR | -9.85% |
2020 | 10.06 Million EUR | 39.91% |
2019 | 7.19 Million EUR | 16.49% |
2018 | 6.17 Million EUR | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 1.05 Million EUR | -19.28% |
2024 Q2 | 965 Thousand EUR | -8.88% |
2024 Q3 | 640 Thousand EUR | -33.68% |
2023 FY | 4.02 Million EUR | -12.48% |
2023 Q4 | 1.31 Million EUR | 0.0% |
2023 Q1 | 1.49 Million EUR | -30.8% |
2023 Q3 | 1.31 Million EUR | 18.52% |
2023 Q2 | 1.1 Million EUR | -25.85% |
2022 Q3 | 2.15 Million EUR | 333.23% |
2022 Q4 | 2.15 Million EUR | 0.0% |
2022 FY | 4.59 Million EUR | -49.3% |
2022 Q2 | 498 Thousand EUR | -69.95% |
2022 Q1 | 1.65 Million EUR | -30.18% |
2021 Q4 | 2.37 Million EUR | 11.09% |
2021 FY | 9.07 Million EUR | -9.85% |
2021 Q3 | 2.13 Million EUR | -9.26% |
2021 Q2 | 2.35 Million EUR | -11.18% |
2021 Q1 | 2.65 Million EUR | -39.71% |
2020 Q3 | 1.99 Million EUR | 0.0% |
2020 FY | 10.06 Million EUR | 39.91% |
2020 Q4 | 4.39 Million EUR | 120.89% |
2019 FY | 7.19 Million EUR | 16.49% |
2018 FY | 6.17 Million EUR | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
BBS-Bioactive Bone Substitutes Oyj | - EUR | -Infinity% |
Nexstim Plc | 7.24 Million EUR | 44.454% |
Revenio Group Oyj | 96.57 Million EUR | 95.832% |